GlassScriptPhysician profile
Jiahuai Tan
NPI 1578891503
$5,478.73
in general payments reported to CMS, 2019-2025
51 companies · $923 in 2025
The $923 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $361 · 2020: $275 · 2021: $318 · 2022: $1,056 · 2023: $1,454 · 2024: $1,092 · 2025: $923.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,295 · Education: $173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,295.34 |
| Education | $173.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $585.66 | 2019-2025 | |
| Gilead Sciences, INC. | $559.49 | 2021-2025 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $457.05 | 2019-2025 | Opdivo, Opdualag, Reblozyl |
| Celgene Corporation | $444.06 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
| Glaxosmithkline, LLC. | $363.65 | 2019-2025 | Ojjaara, Jemperli, Zejula |
| Pharmacyclics LLC, An Abbvie Company | $344.31 | 2020-2023 | Imbruvica |
| Janssen Biotech, INC. | $266.74 | 2020-2025 | Darzalex, Imbruvica, Akeega |
| Merck Sharp & Dohme LLC | $262.66 | 2019-2023 | Keytruda |
| Novartis Pharmaceuticals Corporation | $189.72 | 2019-2024 | |
| Genzyme Corporation | $187.19 | 2022-2025 | |
| Abbvie INC. | $171.96 | 2022-2025 | Venclexta |
| Amgen INC. | $140.03 | 2019-2023 | Nplate, Xgeva, Vectibix |
| Seagen INC. | $107.86 | 2020-2023 | Adcetris |
| Sobi, INC | $99.95 | 2024 | |
| Incyte Corporation | $97.36 | 2019-2024 | Monjuvi |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jiahuai Tan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.